Test Tracks Preclinical Functional Decline
"Since the researchers measured no biomarkers to confirm that Alzheimer's was behind these early changes, they used ApoE4 status as a proxy. While the differences were less stark than between progressors and non-progressors, the partner CFIs did differentiate ApoE carriers and non-carriers by three years into the study...
"This is a really important contribution to the field,” said Jessica Langbaum of Banner Alzheimer's Institute in Phoenix. That the CFI requires no interview is a major plus, she added. Langbaum and other scientists of the Alzheimer’s Prevention Initiative (API) and Novartis are still deciding which patient-reported outcomes to use in the API ApoE4 trial."
http://www.alzforum.org/news/research-n ... al-decline